FORMULATION ARTICLES
-
![Gene editing, gene therapy-GettyImages-930103248]( "Making Personalized Cancer Vaccines Reality: The Manufacturing Challenge Ahead")
Making Personalized Cancer Vaccines Reality: The Manufacturing Challenge AheadPersonalized cancer vaccines are becoming feasible, but scaling fast, affordable, data-driven manufacturing is the central challenge to bringing these individualized therapies to more patients.
-
![Multi ethnic lab team-GettyImages-1255978257]( "Strained Manufacturing, Complexity Stymie In Vivo Progress")
Strained Manufacturing, Complexity Stymie In Vivo ProgressExplicitly mapping delivery challenges to the associated GMP process steps converts biological risk into operational risk.
-
![Medical syringe with blue glass DNA helix-GettyImages-1631239019]( "To Fight Cancer, Gene Editing Needs To Solve Its Delivery Problem")
To Fight Cancer, Gene Editing Needs To Solve Its Delivery ProblemThe choice of delivery dictates the complexity of manufacturing, which in turn determines the eventual cost and accessibility of the therapy.
-
![DNA double helix,Human DNA-GettyImages-1912348507]( "RNA's Evolutionary Logic Is Quietly Rewriting The Future Of Therapeutics: A Conversation With Ahmet Berkyurek")
RNA's Evolutionary Logic Is Quietly Rewriting The Future Of Therapeutics: A Conversation With Ahmet BerkyurekRNA’s adaptive logic is reshaping how therapies are designed. Ahmet Berkyurek explains why embracing evolution—not engineering against it—may unlock the next generation of RNA medicines.
-
![Abstract Modern-GettyImages-490280002]( "Rethinking The \"3:1 Rule\" In LNP Production")
Rethinking The "3:1 Rule" In LNP ProductionA new two-step, ideal-mixing strategy from MIT researchers shows how operating briefly in unstable regions of LNP assembly can unlock precise control of particle size and shape—advancing next-gen RNA manufacturing.
-
![Tumor microenvironment, cancer cells, t-cells, nanoparticles-GettyImages-1449007926]( "Emerging RNA Delivery Strategies For Solid Tumor Oncology")
Emerging RNA Delivery Strategies For Solid Tumor OncologyRNA shows promise in solid tumors, but delivery remains the core challenge. New targeting and delivery strategies aim to overcome tumor barriers and unlock RNA’s full therapeutic potential.
FORMULATION VIDEOS
The emergence of RNA-encapsulated-lipid nanoparticles has introduced a seismic shift in biopharma innovation. But how will the industry adapt to diversifying applications and scales going forward?
Discover the benefits of an LNP system that offers unparalleled durability and sustainability. Eliminate wear parts, plastic waste, and running costs with a system designed for long-term performance and minimal environmental impact.
Russell Johnson, VP Formulation Research for RVAC Medicines, and Aalok Shah, Director of Formulation & Drug Delivery, Strand Therapeutics, share their expectations on which scientific advancements/characteristics will be most important for LNP-delivery of mRNA/RNA cargo in the future.
In this segment, Russell Johnson, VP Formulation Research for RVAC Medicines, and Aalok Shah, Director of Formulation & Drug Delivery, Strand Therapeutics, discuss which ongoing industry efforts to improve LNPs and the RNA/mRNA cargo they're watching closely that could help the RNA industry move beyond hepatic delivery.
ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
![Nova Benchtop]( "Transferring From Microfluidics To A Turbulent Mixer")
What solutions did the client featured in this case study find when they sought help in transferring their formulation process to a turbulent Impinged Jet Mixing (IJM)?
-
![GettyImages-1751659695-laboratory-scientists-computer-analysis-evaluation]( "CQA Assessment Of LNP-Encapsulated IVT mRNA")
Learn more about issued guidelines on Critical Quality Attributes for IVT mRNA vaccines and biotherapeutics to focus on drug substance and LNP-encapsulated drug product assessment using an analyzer system.
-
![GettyImages-1275317360-lab-cell-gene-research-scientist-development-discovery]( "Scale-Up And Manufacturing Of Self-Amplifying RNA-LNPs")
This poster shows the work to scale up COVID-19 self-amplifying RNA-Lipid nanoparticle using PNI developed ionizable lipid and formulation from 0.2, to 50 mg scale using PNI’s Manufacturing Platform.
-
![Outsourcing RNA Feature Image]( "Outsourcing RNA-LNP Production: A Key To Competitive Success")
Manufacturing RNA-containing LNPs demands specialized expertise. Explore some of the challenges of RNA-LNP drug manufacturing and the advantages of outsourcing RNA-LNP formulations.
-
![Gibco sampler]( "The Value Of Premium Gibco Peptones")
Achieve the optimal nutritional balance with diverse supplements tailored for your specific bioprocess that can be added to maintain a nutritionally balanced medium.
-
![iStock-1213444268-vaccine-virus-syringe]( "PEG In LNP Formulations: Addressing Challenges And Seeking Solutions")
Polyethylene glycol and similar variants have driven innovative research for therapies. However, the continued use of PEG poses significant drawbacks.
-
![mRNA GettyImages-1428646288]( "Early Spectroscopic Insights Into RNA Modifications In LNP Formulations With MMS")
Understand how Microfluidic Modulation Spectroscopy (MMS) provides early insights into RNA degradation within LNP formulations, offering a label-free approach to monitoring chemical integrity.
